China Pharma Holdings (CPHI) EBT Margin (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly EBT Margin came in at 153.76% in Q2 2026, down 10225.0% on a YoY basis from N/an in Q2 2025, and down 32.29% quarter-over-quarter from 116.23% in Q1 2026.
Powered by 
Analysis
China Pharma Holdings (CPHI) EBT Margin (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has reported EBT Margin for 17 consecutive years, with 153.76% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 10225.0% year-over-year to 153.76%; the trailing twelve-month figure through Jun 2026 stood at 114.33% (down 3116.0% YoY), and the FY2025 full-year result was 76.91%, up 2767.0% from the prior year.
- EBT Margin slipped to 153.76% in Q2 2026 per CPHI's latest filing, from 116.23% in the prior quarter.
- Across five years, EBT Margin topped out at 24.28% in Q1 2023 and bottomed at 155.48% in Q2 2024.
- Historically, EBT Margin has averaged 77.38% across 5 years, with a median of 66.66% in 2022.
- The sharpest annual moves came in 2025 and 2026: EBT Margin jumped 10397 bps in 2025, then plunged 10225 bps in 2026.
- Over 5 years, EBT Margin stood at 43.28% in 2022, then sank by 32 bps to 57.32% in 2023, then tumbled by 88 bps to 107.98% in 2024, then climbed by 8 bps to 99.68% in 2025, then tumbled by 54 bps to 153.76% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 153.76%, 116.23%, and 99.68% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 29.63% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -4.34% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 12.17% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 44.89% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 47.58% |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | -153.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -153.76% |
| Mar 31, 2026 | -116.23% |
| Dec 31, 2025 | -99.68% |
| Sep 30, 2025 | -86.15% |
| Jun 30, 2025 | -51.51% |
| Mar 31, 2025 | -69.13% |
| Dec 31, 2024 | -107.98% |
| Sep 30, 2024 | -101.61% |
| Jun 30, 2024 | -155.48% |
| Mar 31, 2024 | -69.78% |
| Dec 31, 2023 | -57.32% |
| Sep 30, 2023 | -43.12% |
| Jun 30, 2023 | -54.02% |
| Mar 31, 2023 | -24.28% |
| Dec 31, 2022 | -43.28% |
| Sep 30, 2022 | -40.22% |
| Jun 30, 2022 | -55.07% |
| Mar 31, 2022 | -64.18% |
| Dec 31, 2021 | -33.94% |
| Sep 30, 2021 | -41.78% |